Magle Chemoswed Holding AB
STO:MAGLE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.6
46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Magle Chemoswed Holding AB
Total Liabilities & Equity
Magle Chemoswed Holding AB
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Total Liabilities & Equity
kr273m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Total Liabilities & Equity
kr12.7B
|
CAGR 3-Years
45%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Total Liabilities & Equity
kr6.1B
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Total Liabilities & Equity
kr4.9B
|
CAGR 3-Years
48%
|
CAGR 5-Years
29%
|
CAGR 10-Years
23%
|
|
|
G
|
Genovis AB
STO:GENO
|
Total Liabilities & Equity
kr303.4m
|
CAGR 3-Years
42%
|
CAGR 5-Years
48%
|
CAGR 10-Years
25%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Total Liabilities & Equity
kr1.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
13%
|
|
Magle Chemoswed Holding AB
Glance View
Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
See Also
What is Magle Chemoswed Holding AB's Total Liabilities & Equity?
Total Liabilities & Equity
273m
SEK
Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's Total Liabilities & Equity amounts to 273m SEK.
What is Magle Chemoswed Holding AB's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
12%
Over the last year, the Total Liabilities & Equity growth was 8%. The average annual Total Liabilities & Equity growth rates for Magle Chemoswed Holding AB have been 11% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
